BHVN Biohaven Pharmaceutical Holding Co Ltd

Price (delayed)

$133.61

Market cap

$8.74B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.41

Enterprise value

$8.71B

Biohaven Pharmaceutical Holding Company Ltd. is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including ...

Highlights
The company's gross profit has surged by 91% QoQ
BHVN's revenue has soared by 78% QoQ
Biohaven Pharmaceutical Holding's equity has plunged by 64% from the previous quarter
Biohaven Pharmaceutical Holding's net income has decreased by 46% YoY and by 3.5% QoQ

Key stats

What are the main financial stats of BHVN
Market
Shares outstanding
65.4M
Market cap
$8.74B
Enterprise value
$8.71B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
45.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
45.93
Earnings
Revenue
$189.53M
EBIT
-$815.48M
EBITDA
-$794.76M
Free cash flow
-$831.71M
Per share
EPS
-$14.41
Free cash flow per share
-$12.77
Book value per share
-$6.97
Revenue per share
$2.91
TBVPS
$12.11
Balance sheet
Total assets
$845.89M
Total liabilities
$1.24B
Debt
$274.14M
Equity
-$453.88M
Working capital
$267.45M
Liquidity
Debt to equity
-0.6
Current ratio
1.67
Quick ratio
1.34
Net debt/EBITDA
0.04
Margins
EBITDA margin
-419.3%
Gross margin
76.6%
Net margin
-468.8%
Operating margin
-391.2%
Efficiency
Return on assets
-107.1%
Return on equity
N/A
Return on invested capital
-192.9%
Return on capital employed
-182.5%
Return on sales
-430.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BHVN stock price

How has the Biohaven Pharmaceutical Holding stock price performed over time
Intraday
-0.88%
1 week
-5.7%
1 month
-1.75%
1 year
73.52%
YTD
55.89%
QTD
-3.82%

Financial performance

How have Biohaven Pharmaceutical Holding's revenue and profit performed over time
Revenue
$189.53M
Gross profit
$145.12M
Operating income
-$741.42M
Net income
-$888.51M
Gross margin
76.6%
Net margin
-468.8%
The net margin has soared by 92% year-on-year and by 42% since the previous quarter
BHVN's operating margin has surged by 92% year-on-year and by 43% since the previous quarter
The company's gross profit has surged by 91% QoQ
BHVN's revenue has soared by 78% QoQ

Growth

What is Biohaven Pharmaceutical Holding's growth rate over time

Valuation

What is Biohaven Pharmaceutical Holding stock price valuation
P/E
N/A
P/B
N/A
P/S
45.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
45.93
The EPS has declined by 30% year-on-year
Biohaven Pharmaceutical Holding's equity has plunged by 64% from the previous quarter
BHVN's revenue has soared by 78% QoQ
The price to sales (P/S) is 36% less than the last 4 quarters average of 72.1

Efficiency

How efficient is Biohaven Pharmaceutical Holding business performance
The return on sales has surged by 92% year-on-year and by 43% since the previous quarter
BHVN's ROA is up by 24% year-on-year and by 10% since the previous quarter
BHVN's ROIC is up by 22% since the previous quarter

Dividends

What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BHVN.

Financial health

How did Biohaven Pharmaceutical Holding financials performed over time
The total assets is 32% smaller than the total liabilities
BHVN's total liabilities has surged by 170% year-on-year
The total assets has surged by 99% year-on-year but it has declined by 16% since the previous quarter
The debt is 160% greater than the equity
Biohaven Pharmaceutical Holding's equity has plunged by 64% from the previous quarter
BHVN's debt to equity is up by 39% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.